Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.
Advertisement

Related Content

GW Insists Sativex Is Approvable In U.K. Despite Phase III Failure In MS Pain
GW Insists Sativex Is Approvable In U.K. Despite Phase III Failure In MS Pain
Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus
Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus
CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications
CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications
Canadian Firms Partner On Cannabinoid-Based Therapies For Mood Disorders
Canadian Firms Partner On Cannabinoid-Based Therapies For Mood Disorders
Cesamet Launch Will Highlight Longer Duration of Action Vs. Marinol
Cesamet Launch Will Highlight Longer Duration of Action Vs. Marinol

Topics

Advertisement
UsernamePublicRestriction

Register

PS065632

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel